NVP-QAW039 Powder Briefing
Fevipiprant is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D₂ receptor 2. As of 2016, it is in phase III clinical trials for the treatment of asthma.
Product Uses
Fevipiprant has been used in trials studying the treatment of Asthma, Atopic Dermatitis, Allergic Rhinitis and hair loss.
Product Function
Fevipiprant is an oral competitive antagonist of CRTH2. Early-phase trials have demonstrated safety and potential efficacy in patients with asthma, specifically, improvement in FEV 1 and eosinophilic airway inflammation.
Product Benefits
Fevipiprant is the for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of Setipiprant have focused on different chemical forms of the combining it with various nanoparticles to enhance delivery.
Fevipiprant reduces eosinophilic airway inflammation and is well tolerated in patients with persistent moderate-to-severe asthma and raised sputum eosinophil counts despite inhaled corticosteroid treatment. Fevipiprant demonstrates a favorable safety profile.
How to process the order?
- send us an email toinfo@bulkrawspharma.com with the following details: product names, quantity and your special requests (eg. need custom produced)
- we quote and confirm your request details
- we ship your order after payment done and offer tracking code & packing pictures within 1-3 days
- we will keep you updated of your order status
- order received and review our services
Payment terms
MoneyGram, Western Union, Bitcoin,T/T Bank transfer,USDT.escrow alibaba (credit card,paypal),etc.
Reviews
There are no reviews yet.